- Home
- AGEN vs AVTX Comparison
AGEN vs AVTX Comparison
Compare AGEN & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- AVTX
- Stock Information
- Founded
- AGEN 1994
- AVTX 2011
- Country
- AGEN United States
- AVTX United States
- Employees
- AGEN N/A
- AVTX N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- AGEN Health Care
- AVTX Health Care
- Exchange
- AGEN Nasdaq
- AVTX Nasdaq
- Market Cap
- AGEN 38.1M
- AVTX 88.4M
- IPO Year
- AGEN 2000
- AVTX 2015
- Fundamental
- Price
- AGEN $1.60
- AVTX $6.85
- Analyst Decision
- AGEN Buy
- AVTX Strong Buy
- Analyst Count
- AGEN 4
- AVTX 7
- Target Price
- AGEN $8.00
- AVTX $34.33
- AVG Volume (30 Days)
- AGEN 500.1K
- AVTX 110.3K
- Earning Date
- AGEN 05-06-2025
- AVTX 05-12-2025
- Dividend Yield
- AGEN N/A
- AVTX N/A
- EPS Growth
- AGEN N/A
- AVTX N/A
- EPS
- AGEN N/A
- AVTX N/A
- Revenue
- AGEN $103,463,000.00
- AVTX $441,000.00
- Revenue This Year
- AGEN $4.03
- AVTX N/A
- Revenue Next Year
- AGEN $5.57
- AVTX N/A
- P/E Ratio
- AGEN N/A
- AVTX N/A
- Revenue Growth
- AGEN N/A
- AVTX N/A
- 52 Week Low
- AGEN $1.44
- AVTX $5.99
- 52 Week High
- AGEN $19.69
- AVTX $20.85
- Technical
- Relative Strength Index (RSI)
- AGEN 28.09
- AVTX 41.31
- Support Level
- AGEN $1.44
- AVTX $7.88
- Resistance Level
- AGEN $1.77
- AVTX $9.00
- Average True Range (ATR)
- AGEN 0.14
- AVTX 0.83
- MACD
- AGEN 0.03
- AVTX -0.03
- Stochastic Oscillator
- AGEN 32.00
- AVTX 1.47
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).